Educational only. PT-141 / bremelanotide is not currently an available YourHealthRx offering. This article is published for science and regulatory education. It does not indicate that YourHealthRx offers, prescribes, dispenses, compounds, ships, or guarantees access to PT-141 or bremelanotide. The FDA-approved bremelanotide product, Vyleesi, is dispensed only on a clinician's evaluated prescription, for a specific FDA-approved indication. Nothing here is medical advice, dosing guidance, or a treatment recommendation.
PT-141 is the investigational name many people still use for bremelanotide, a synthetic peptide analog of alpha-melanocyte-stimulating hormone. The FDA-approved bremelanotide product, Vyleesi, is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD, when low desire causes marked distress or interpersonal difficulty and is not due to another medical, psychiatric, relationship, medication, or substance-related cause (FDA label).
That indication is narrow. Vyleesi is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance (FDA label). This is the first compliance point YourHealthRx should make clearly before anyone reduces PT-141 to "the libido peptide."
The more accurate framing is this: PT-141 / bremelanotide is a melanocortin receptor agonist with human Phase 3 evidence in a defined premenopausal HSDD population, but its clinical use requires careful patient selection, cardiovascular screening, side-effect counseling, and regulatory discipline.
Bottom line: PT-141 / bremelanotide is a melanocortin receptor agonist with diagnosis-specific Phase 3 evidence for acquired, generalized HSDD in premenopausal women — not a general-purpose libido or performance peptide.
YourHealthRx framing: diagnosis fit, cardiovascular screening, and labeled-dose discipline come before access — not after.
Quick Takeaways
- PT-141 is bremelanotide, a melanocortin receptor agonist with MC4R relevance at therapeutic doses (PubMed mechanism review).
- FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women — not for men, postmenopausal women, or performance enhancement (FDA label).
- Phase 3 RECONNECT trials randomized 1,267 women and showed statistically significant improvements in desire and reductions in distress vs placebo (PubMed RECONNECT).
- Labeled dosing limits matter: the FDA prescribing information caps individual dose, 24-hour frequency, and monthly use; the specifics belong on the label, not in a blog post (FDA label).
- Cardiovascular contraindication: uncontrolled hypertension or known cardiovascular disease; each dose can transiently raise blood pressure and lower heart rate (FDA label).
- Common adverse effects include nausea (~40%), flushing (~20%), injection-site reactions (~13%), and headache (~11%) (LiverTox).
What PT-141 Actually Is
PT-141 is bremelanotide. It is often discussed in peptide communities because it is a peptide analog, but its clinical identity is more specific: it is a melanocortin receptor agonist. Melanocortin receptors are involved in several body systems, including central nervous system signaling, pigmentation pathways, appetite biology, and sexual response.
That central nervous system angle matters. PT-141 is not simply a blood-flow drug. It is not best understood as a direct equivalent to PDE5 inhibitors like sildenafil or tadalafil. Instead, the bremelanotide mechanism is usually discussed in relation to melanocortin receptor activation, especially MC4R relevance at therapeutic doses, and downstream effects on central pathways involved in desire (PubMed).
The mechanism is still not completely resolved. A neurobiology review explains that bremelanotide is a melanocortin receptor agonist that nonselectively activates several receptor subtypes, with MC4R most relevant at therapeutic doses, and animal data suggest effects on dopamine release in hypothalamic regions involved in female sexual function (PubMed).
The clinical takeaway is simple: bremelanotide should be framed as a centrally acting desire-pathway therapy, not as a broad "performance enhancer." That distinction helps keep the content accurate and compliant.
The FDA-Approved Use
The FDA-approved product Vyleesi is bremelanotide for subcutaneous use. As described in the official FDA prescribing information, the labeled product, route, dose, and timing are tightly defined for an evaluated patient population (FDA label). This article does not reproduce dosing instructions; if a clinician determines that Vyleesi is appropriate, the labeled regimen is what governs use.
The same FDA label sets explicit upper limits on dose frequency and monthly use (FDA label). Those limits exist because many peptide discussions online ignore labeled dosing, patient selection, and risk screening — none of which can be substituted with a self-administration plan from the internet.
The approved indication is not "low libido" in a casual sense. It is acquired, generalized HSDD in premenopausal women, characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not better explained by another condition, relationship problem, medication, or drug substance (FDA label).
That diagnostic context is essential. Sexual desire is biopsychosocial. It can be influenced by relationship factors, stress, sleep, medications, depression, anxiety, trauma history, hormones, pain, pelvic floor issues, metabolic health, and many other variables. A clinician-led model should screen before prescribing and avoid presenting a peptide as a shortcut around evaluation.
What the Phase 3 Evidence Showed
The pivotal RECONNECT program included two identical Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials of bremelanotide 1.75 mg used subcutaneously as needed in premenopausal women with HSDD (PubMed).
Across the trials, 1,267 women were randomized, with 1,247 included in the safety population and 1,202 in the modified intent-to-treat efficacy population (PubMed). The co-primary endpoints were change in sexual desire using the Female Sexual Function Index desire domain and change in distress related to low sexual desire using the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 (PubMed).
From baseline to end of study, women receiving bremelanotide had statistically significant increases in sexual desire compared with placebo: study 301 showed a 0.30 improvement with P<.001, study 302 showed a 0.42 improvement with P<.001, and the integrated studies showed a 0.35 improvement with P<.001 (PubMed).
The trials also showed statistically significant reductions in distress related to low sexual desire compared with placebo: study 301 showed -0.37 with P<.001, study 302 showed -0.29 with P=.005, and the integrated studies showed -0.33 with P<.001 (PubMed).
This is real clinical evidence. It is also not a reason to exaggerate. The evidence supports an approved, diagnosis-specific use in a defined population. It does not support universal claims about libido, relationships, male sexual function, postmenopausal sexual dysfunction, athletic performance, or "enhancement."
Safety and Tolerability
The most common adverse reactions in the FDA label include nausea, flushing, injection site reactions, headache, and vomiting (FDA label). LiverTox summarizes common side effects as nausea at about 40%, flushing at about 20%, injection-site reactions at about 13%, and headache at about 11% (LiverTox).
Nausea is not a footnote. It is one of the most recognizable tolerability issues with bremelanotide and should be included in any balanced educational discussion. The Phase 3 trials also reported more nausea, flushing, and headache in bremelanotide-treated patients than placebo, with these events occurring in 10% or more of patients in both studies (PubMed).
The cardiovascular warning is also important. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease, and the label warns that each dose can cause a transient increase in blood pressure and decrease in heart rate that usually resolves within 12 hours (FDA label).
The label also warns about focal hyperpigmentation, including face, gingiva, and breast involvement, and notes that it was reported by 1% of patients receiving up to eight doses per month; patients with dark skin were more likely to develop focal hyperpigmentation (FDA label). LiverTox also notes uncommon adverse reactions including increased blood pressure, severe nausea and vomiting, arthralgia, restless leg syndrome, and local hyperpigmentation (LiverTox).
For clinical screening, the practical conversation should include blood pressure, cardiovascular history, medication review, pregnancy status, nausea risk, pigmentation risk, diagnosis fit, relationship and mental health context, and whether other causes of low desire have been evaluated.
Why the Internet Gets PT-141 Wrong
PT-141 gets simplified because the hook is easy: "libido peptide." That hook may get clicks, but it strips out the most important context.
The better educational framing is more precise. PT-141 / bremelanotide is a melanocortin receptor agonist. It has an FDA-approved product for acquired, generalized HSDD in premenopausal women. It is not labeled for men, postmenopausal women, or sexual performance enhancement. Its mechanism appears central rather than purely vascular. Its tolerability profile includes nausea and flushing, and it has cardiovascular and pigmentation warnings.
That is the difference between compliant education and irresponsible marketing. A peptide telehealth brand should not need to overstate a compound to make it interesting. The truth is already interesting enough.
Evidence Ladder
For YourHealthRx, PT-141 / bremelanotide should sit on this evidence ladder:
- Mechanism: Melanocortin receptor agonist, with MC4R relevance in desire-pathway discussions.
- Human evidence: Two Phase 3 randomized trials in premenopausal women with acquired, generalized HSDD.
- Regulatory status: FDA-approved as Vyleesi for a narrow indication.
- Limitations: Not indicated for men, postmenopausal women, or performance enhancement.
- Safety: Nausea, flushing, injection-site reactions, headache, vomiting, blood pressure changes, cardiovascular contraindications, and focal hyperpigmentation.
- Clinical model: Diagnosis, screening, and counseling matter as much as access.
That ladder keeps the message strong without turning the article into an ad.
Bottom Line
PT-141 / bremelanotide is one of the more clinically grounded compounds in the sexual-health peptide conversation because it has an FDA-approved product and Phase 3 human evidence. But that same FDA status makes the boundaries even more important.
The most accurate YourHealthRx position is straightforward: PT-141 / bremelanotide is a melanocortin receptor agonist with diagnosis-specific evidence for acquired, generalized HSDD in premenopausal women, plus clear labeling limits, side effects, and cardiovascular screening requirements. That is the kind of framing that builds trust.
Informational only. This article is for informational and educational purposes only. It is not medical advice, does not create a patient-clinician relationship, and should not be used to diagnose, treat, cure, or prevent any disease. Anyone considering any therapy affecting sexual function should work with a licensed clinician who can evaluate diagnosis fit, cardiovascular history, blood pressure, medications, pregnancy status, mental health, and other clinical context. Regulatory, pharmacy, telehealth, and compounding questions related to peptides affecting sexual function should be reviewed with a specialized healthcare attorney before business action is taken.
Sources: FDA Vyleesi label · RECONNECT Phase 3 (PubMed) · Bremelanotide mechanism review (PubMed) · LiverTox: Bremelanotide